Ketamine A ‘Lifesaving’ Aid for Depression?
Aug. 21, 2018 — Ketamine, a widely used anesthetic that’s also an illicit party drug, has taken on a new role in recent years: treating severe depression in people who have not responded to standard treatment. Researchers have called it the most exciting breakthrough in the field of depression research in the past half-century.
One form of the drug, being developed as a nasal spray called esketamine, is in the final stages of testing needed before it can go to the FDA for approval.
A Quick Response to Ketamine
Eight percent of American adults have depression, an often debilitating and sometimes fatal disease. People with major depression are 20 times more likely to attempt suicide. Talk therapy and antidepressant medications often help, but such treatments leave one in three people with depression searching for more help.
No Action from FDA — Yet
The FDA allows doctors to prescribe approved medications “off-label,” or for purposes other than those for which they were first approved. Ketamine is one such medication. The FDA approved it as an anesthetic in 1970. Its off-label uses have not been limited to depression treatment.
‘No Easy Answer’ to Ketamine’s Use
Last year, Sanacora and several colleagues published a statement in a leading psychiatric journal in response to the “rapidly escalating demand for clinical access to ketamine treatment and an increasing number of clinicians willing to provide it.”
The authors addressed ketamine dosing, safety, patient follow-up after treatment, and other issues that remain to be resolved.
Ketamine’s Potential for Abuse
Of particular concern to parents of the participants: ketamine’s potential for abuse. Even in clinical doses, the drug sometimes produces short-lived psychedelic side effects like euphoria, hallucinations, and out-of-body experiences. Those effects have made it a popular club drug.
Focusing on Drug’s Positives
Meanwhile, Zarate has set his sights on another potential ketamine-related therapy. When you take ketamine, your body breaks it down into two dozen different byproducts, called metabolites. Zarate and his colleagues are now focusing their research on one of those metabolites, which appears to offer ketamine’s antidepressant effects without its side effects or potential for abuse.
“We will approach the FDA hopefully sometime this year and begin studies hopefully next year,” says Zarate. “If ketamine makes it to the market — and by all means that looks very promising — that paves the way for further ketamine-like treatments without the side effects.”